Varex Imaging Corporation reported a modest 1% year-over-year revenue growth for Q2 2026, totaling $216 million, driven primarily by its Medical segment, which generated $156 million. Despite a non-GAAP gross margin of 34%—at the high end of guidance—overall profitability was impacted by a GAAP net loss of $8 million and a $1.8 million noncash charge related to an equity investment. The company’s debt refinancing efforts have improved its capital structure, reducing outstanding debt and annual interest expenses, which enhances financial flexibility moving forward.
The revenue growth and operational challenges highlight a mixed outlook for Varex. While the Americas showed a 13% revenue increase, the EMEA region experienced a 16% decline, indicating regional disparities in demand. The ongoing ramp-up of the India manufacturing facility is expected to create future efficiencies, although it currently poses a headwind to margins.
Investors should watch Varex’s ability to manage inventory levels and leverage its expanding OEM pipeline in photon counting technology, as these factors could significantly influence future earnings and market positioning.
Source: fool.com